Technology in Cancer Research & Treatment最新文献

{"title":"Salivary SIRT3 Levels in Gutka and Alcohol Consumers: A Cross-Sectional Study on Habit-Associated Molecular Changes.","authors":"Junaid Ahmed, Shubham Pawar, Nandita Shenoy, Neelam Pawar, Nanditha Sujir","doi":"10.1177/15330338251408546","DOIUrl":"10.1177/15330338251408546","url":null,"abstract":"<p><p>BackgroundSirtuin-3 (SIRT3) regulates the production of cellular reactive oxygen species (ROS). This study aims to elucidate the molecular mechanisms involved in oral lesion development by exploring the relationship between SIRT3 expression, gutka consumption, and oral disease progression, with the objective of identifying potential biomarkers for early detection and risk assessment.MethodsA cross-sectional study was conducted among individuals who regularly underwent oral health check-ups, excluding patients with premalignant and oral cancers from the study. Participants were categorized into three groups: Case 1 (gutka and alcohol consumers), Case 2 (gutka consumers without alcohol), and Control (non-consumers). Unstimulated saliva samples were collected and analysed using ELISA to measure SIRT3 levels. Statistical comparisons were performed using ANOVA followed by post hoc Tukey testsResultsThe mean SIRT3 levels were 7.57 ± 3.23 ng/mL (Case 1), 8.17 ± 2.87 ng/mL (Case 2), and 9.9 ± 2.78 ng/mL (control). The differences between the groups were statistically significant (p = .036), with the greatest difference observed between the case 1 group and the control group.ConclusionSIRT3 levels were lowest in individuals who consumed gutka and alcohol and were significantly lower than those in the control group. These findings suggest a potential negative impact of gutka and alcohol consumption on SIRT3 levels.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338251408546"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13176558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147933788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence-Enabled Continuous HER2 Assessment: A Patient Selection Framework for the Antibody-Drug Conjugate Era.","authors":"Min-Hsiang Chang, Hsin-Hsiu Tsai, Chun-Jui Chien, Jian-Chiao Wang","doi":"10.1177/15330338261500841","DOIUrl":"https://doi.org/10.1177/15330338261500841","url":null,"abstract":"<p><p>IntroductionAntibody-drug conjugates have expanded HER2-targeted therapy to HER2-low breast cancer, yet categorical immunohistochemistry scoring inadequately supports patient selection at expression boundaries where interobserver agreement is suboptimal.MethodWe propose that artificial intelligence-enabled continuous quantification addresses this gap by preserving expression gradients essential for treatment eligibility decisions while maintaining pathologist interpretability.ResultUsing a pilot dataset (n=66), we demonstrate that data-driven thresholds derived from continuous scores can support three clinically relevant decision points: anti-HER2 therapy eligibility, in situ hybridization triage, and HER2-low identification for ADC candidacy. Bootstrap validation and cross-validation analyses supported threshold robustness.ConclusionThis transition from categorical boundaries to quantitative spectra may contribute to precision in patient selection, pending validation with treatment outcome data.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261500841"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149207994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Lightweight Skeletal Muscle Intelligent Segmentation Network Based on Planning CT for Cervical Cancer Radiotherapy.","authors":"Liming Lu, Xiwei Chen, Jing Liu, Gongfu Chen, Junyue Shi, Zhe Wu, Gaokui He","doi":"10.1177/15330338261446535","DOIUrl":"10.1177/15330338261446535","url":null,"abstract":"<p><p>PurposeA lightweight deep learning network SMA-Net was proposed to intelligently segment the skeletal muscle of the third lumbar (L3) level in patients with cervical cancer radiotherapy, and the segmentation performance of the network was evaluated.Methods and MaterialsA total of 160 eligible patients with cervical cancer admitted to the oncology department of our hospital from September 2021 to June 2024 were randomly divided into training set (N = 112), validation set (N = 16) and test set (N = 32) according to 7 : 1 : 2. The lightweight Mamba architecture is introduced into the UNet network, and the SAB and CAB attention mechanisms are introduced on the skip connection. The attention mechanism is used to suppress the irrelevant information in the image and highlight the important local features. The trained network is geometrically evaluated on the test set for segmentation performance, comparison of manual segmentation and predicted skeletal muscle area (SMA). Compare the parameters and computations of SMA-Net with existing networks.ResultsThe dice similarity coefficient of SMA-Net network for skeletal muscle segmentation was 89.16%, the sensitivity SEN was 88.21%, the positive predictive value PPV was 90.13% and the 95% Hausdorff distance was 5.30mm. Manual segmentation is basically close to the predicted SMA. Our proposed network for cervical cancer patients predicted sarcopenia with 87.5% accuracy, 92.31% precision, 80% recall, 85.72% F1-Score, and 0.871 AUC. The calculation amount of SMA-UNet network is 1.50 GFLOPS, and the parameter amount is 1.24 M. The radiologist's scores show that minor and no revision accounted for 93.75% on manual revision of skeletal muscle.ConclusionThe lightweight SMA-Net proposed in this study can accurately segment L3 skeletal muscle and quickly calculate its area, which basically meets the clinical application and is convenient for clinical deployment. It is helpful for clinicians to quickly diagnose sarcopenia in patients with cervical cancer, save medical resources, reduce the workload of physicians, and improve diagnostic efficiency.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261446535"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13133491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147781794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: Functional Changes of Dendritic Cells in C6 Glioma-Bearing Rats That Underwent Combined Argon-Helium Cryotherapy and IL-12 Treatment.","authors":"","doi":"10.1177/15330338261428220","DOIUrl":"10.1177/15330338261428220","url":null,"abstract":"","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261428220"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147378604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Historic Real-World Outcomes and Future Benchmarks for Patients with Diffuse Large B-Cell Lymphoma Receiving First- and Second-Line Therapy in Austria - a Large Single-Center Experience.","authors":"Michael Leisch, Dominik Kiem, Christoph Grabmer, Anton Kugler, Gianfranco Pocobelli, Mayer Marie-Christina, Bernd Schöpf, Alexander Egle, Richard Greil, Thomas Melchardt","doi":"10.1177/15330338251410356","DOIUrl":"10.1177/15330338251410356","url":null,"abstract":"<p><p>BackgroundDiffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin-lymphoma. Although it can be cured in many patients, a significant proportion of patients fail the primary treatment and require second-line treatment. Currently, only limited data on real-world outcomes with standard therapies in Austrian patients with DLBCL are available, and while novel therapies are emerging, no historical benchmarks have been established to serve as a reference for these novel treatments.MethodsWe performed a retrospective, single-center analysis of patients with DLBCL diagnosed between 2010 and 2018 who had been treated with standard therapies. To establish efficacy benchmarks for novel therapies, we applied both clinical-trial and real-world-derived criteria to analyze the outcomes of patients potentially eligible for novel or future treatments.ResultsAlthough many patients can be cured with frontline therapy, outcomes are poor, especially in high-risk patients. Patients failing frontline therapy, especially those fulfilling the chimeric antigen-receptor (CAR) T-cell eligibility criteria, had dismal outcomes, and very few patients achieved long-term remission. Our data provide benchmark outcomes for patients eligible for novel treatments such as antibody-drug-conjugate (ADC) or CAR T-cell therapy-based treatments for potential future comparative analyses.ConclusionsPatients with DLBCL treated in Austria showed comparable outcomes to those reported in other real-world studies. Overall, standard chemotherapy-based approaches provide unsatisfactory outcomes in high-risk patients and patients in whom frontline therapy fails. Because many patients are now eligible for alternative first- and second-line treatments, such as ADC-based or CAR T-cell therapy, our efficacy benchmarks can serve for the future evaluation of these therapies in the Austrian healthcare environment.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338251410356"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12783576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145935005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"The Value of Topological Radiomics Analysis in Predicting Malignant Risk of Pulmonary Ground-Glass Nodules: A Multi-Center Study\".","authors":"","doi":"10.1177/15330338261454488","DOIUrl":"10.1177/15330338261454488","url":null,"abstract":"","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261454488"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13198631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147989119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retracted: Expression of p-Akt and COX-2 in Gastric Adenocarcinomas and Adenovirus Mediated Akt1 and COX-2 ShRNA Suppresses SGC-7901 Gastric Adenocarcinoma and U251 Glioma Cell <i>Growth In Vitro</i> and <i>In Vivo</i>.","authors":"","doi":"10.1177/15330338261426145","DOIUrl":"10.1177/15330338261426145","url":null,"abstract":"","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261426145"},"PeriodicalIF":2.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147481700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Radiation Therapy for Primary Bone Malignancies.","authors":"Luyuan Li, Wensi Tao, Josiane E Eid, Shweta Gupta, Shuhua Zheng, Crystal Seldon Taswell, Jonathan C Trent","doi":"10.1177/15330338261425345","DOIUrl":"10.1177/15330338261425345","url":null,"abstract":"<p><p>Primary bone malignancies - including chordoma, chondrosarcoma, osteosarcoma, and Ewing sarcoma - originate from bone or cartilage cells and often develop in anatomically complex or surgically challenging regions. While surgical resection remains the standard of care for most localized tumors, radiation therapy (RT) has become an increasingly integral component of multidisciplinary management, particularly when complete surgical excision is not feasible, margins are close or positive, or the tumor is adjacent to critical structures. Historically, conventional photon-based RT has shown limited efficacy in many of these tumors due to factors such as relative radioresistance and proximity to radiosensitive normal tissues. However, advances in conformal photon techniques such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT), along with hadron-based approaches like proton beam therapy (PBT) and carbon ion radiation therapy (CIRT), have expanded the therapeutic potential of RT in bone sarcomas. This review highlights the evolving role of RT in the management of primary bone malignancies, with a focus on technological advances, clinical outcomes, ongoing trials, and future directions in the field.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261425345"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12988310/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147443882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating Multi-Omics Mendelian Randomization and Functional Validation to Identify Novel Apoptosis Regulators in Follicular Lymphoma.","authors":"Bin Zhu, Suli Wang, Wenli Zhao","doi":"10.1177/15330338261471599","DOIUrl":"10.1177/15330338261471599","url":null,"abstract":"<p><p>IntroductionDysregulation of apoptosis is a hallmark of follicular lymphoma (FL), yet the causal genetic drivers remain incompletely understood. This study aimed to identify causal apoptosis-related genes in FL and validate their functional roles.MethodsWe conducted a multi-omics Mendelian randomization (MR) study, integrating summary statistics from a large-scale FL genome-wide association study with data on methylation (mQTL), expression (eQTL), and protein (pQTL) quantitative trait loci. Summary data-based MR (SMR) and colocalization analyses were used to identify candidate causal genes. Independent external transcriptomic cohorts were utilized to validate the gene correlations, and evaluate the clinical prognostic relevance of the identified candidates. Key findings were then validated in FL patient tissues using RT-qPCR, and the functional role and downstream molecular mechanisms of the top candidate gene were systematically characterized through <i>in vitro</i> phenotypic characterization, drug sensitivity testing, and mechanistic signaling analyses.ResultsOur MR analysis identified several genes with causal links to FL risk, with integrative analysis highlighting <i>IER3IP1</i>, <i>PRKCZ</i>, and <i>CD40.</i> Notably, <i>PRKCZ</i> and <i>CD40</i> exhibited significant correlation, whereas <i>IER3IP1</i> displayed an independent regulatory pattern. Clinical tissue validation confirmed that <i>IER3IP1</i> mRNA levels were significantly elevated in FL patient tissues. Functional studies in an FL cell line demonstrated that <i>IER3IP1</i> acts as an oncogene, promoting proliferation, colony formation, and migration while inhibiting apoptosis. Mechanistically, <i>IER3IP1</i> depletion promoted FOXO1-mediated transcriptional upregulation of CD20 via the XBP1/FOXO1 signaling axis, which concomitantly activated the intrinsic apoptotic pathway and significantly enhanced the sensitivity of FL cells to Rituximab-mediated cytotoxicity and apoptosis.Additionally, survival analysis revealed that <i>CD40</i> serves as a strong prognostic indicator, with its low expression correlated with poorer progression-free survival and overall survival in FL patients.ConclusionsThis study provides the genetic and functional evidence establishing <i>IER3IP1</i> as a novel causal oncogene in the pathogenesis of FL. Our findings elucidate the critical role of the IER3IP1-mediated XBP1/FOXO1/CD20 axis in targeted therapy resistance, highlighting <i>IER3IP1</i> as a promising therapeutic target to restore apoptotic activity and improve Rituximab sensitivity.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261471599"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13396582/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148579948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moderate Hypofractionated Helical Tomotherapy for Localized Prostate Cancer in Older Patients: A Single-Institution Study of Toxicity and Outcomes.","authors":"Lingling Meng, Yupeng Di, Lin Ma, Baolin Qu","doi":"10.1177/15330338261439193","DOIUrl":"10.1177/15330338261439193","url":null,"abstract":"<p><p>IntroductionThe optimal management of localized prostate cancer (PCa) in the \"oldest-old\" demographic presents a unique clinical challenge, requiring a careful balance between oncological control and the preservation of quality of life. This study aims to evaluate the safety, toxicity profile, and clinical outcomes of moderately hypofractionated helical tomotherapy (HT) in a cohort of patients aged 75 years and older with localized PCa.Materials and MethodsIn this retrospective cohort study, we analyzed 51 consecutive patients with a median age of 79 years treated between 2016 and 2022. All patients received 69 Gy in 25 fractions (2.76 Gy/fraction) via the HT platform. Risk stratification was performed using the D'Amico classification, revealing that the majority were high-risk (52.9%) or intermediate-risk (43.1%). Clinical outcomes included biochemical relapse-free survival (BRFS), cancer-specific survival (CSS), and overall survival (OS). Toxicity grading followed CTCAE v4.0 criteria, and Quality of Life (QoL) was evaluated through the International Prostate Symptom Score (IPSS) and a single-item index.ResultsAt a median follow-up of 38 months, the 5-year BRFS, CSS, and OS rates were 83.3%, 80.1%, and 68.8%, respectively. Acute Grade 2 genitourinary and gastrointestinal toxicities occurred in 25.5% and 27.5% of the subjects. Late Grade 3 complications were rare (1 GU, 4 GI). Significant longitudinal improvements in IPSS and QoL were observed within 3 months post-treatment (<math><mrow><mi>p</mi><mo><</mo><mn>0.001</mn></mrow></math>).ConclusionModerately hypofractionated HT may be a safe and effective treatment for elderly PCa patients, suggesting potential for excellent oncological control and symptomatic relief.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261439193"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13033883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147575339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}